Baker Ellis Asset Management LLC Buys 35 Shares of Eli Lilly and Company (NYSE:LLY)

Baker Ellis Asset Management LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 8.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 435 shares of the company’s stock after acquiring an additional 35 shares during the quarter. Baker Ellis Asset Management LLC’s holdings in Eli Lilly and Company were worth $338,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Investment Research & Advisory Group Inc. raised its stake in shares of Eli Lilly and Company by 94.6% in the first quarter. Investment Research & Advisory Group Inc. now owns 6,269 shares of the company’s stock worth $4,877,000 after purchasing an additional 3,048 shares during the last quarter. First Bank & Trust purchased a new position in shares of Eli Lilly and Company in the first quarter worth $425,000. WoodTrust Financial Corp raised its stake in shares of Eli Lilly and Company by 18.6% in the first quarter. WoodTrust Financial Corp now owns 2,326 shares of the company’s stock worth $1,809,000 after purchasing an additional 364 shares during the last quarter. MCF Advisors LLC raised its stake in shares of Eli Lilly and Company by 5.4% in the first quarter. MCF Advisors LLC now owns 2,855 shares of the company’s stock worth $2,221,000 after purchasing an additional 145 shares during the last quarter. Finally, Opinicus Capital Inc. raised its stake in shares of Eli Lilly and Company by 1.1% in the first quarter. Opinicus Capital Inc. now owns 3,625 shares of the company’s stock worth $2,820,000 after purchasing an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the transaction, the insider now directly owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, EVP Johna Norton sold 7,056 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the transaction, the insider now directly owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The disclosure for this sale can be found here. Insiders sold a total of 789,704 shares of company stock valued at $672,385,964 over the last 90 days. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of research reports. Argus upped their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Citigroup upped their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, June 24th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $812.72.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $905.38 on Friday. The firm has a market cap of $860.48 billion, a price-to-earnings ratio of 133.34, a price-to-earnings-growth ratio of 1.97 and a beta of 0.36. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The business has a 50-day moving average price of $814.40 and a 200-day moving average price of $739.86. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $915.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.62 earnings per share. As a group, equities research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.